If you want a cheap but out-of-this-world vacation, a short tour of the universe may be just what you are looking for. This video was posted by Adam Frank last January on a National Public Radio blog called 13.7: Cosmos and Culture.
Evolving hERG Inhibition Model
Modeling hERG inhibition has significantly gained popularity since 2005, when the FDA recognized the correlation between hERG inhibition and a prolonged QT interval by issuing guidance for the…
Physiologically-Based Pharmacokinetic (PBPK) Model for Prediction of Tobramycin Pulmonary Absorption and Pharmacokinetics in Children
To fit an absorption-pharmacokinetic model for simulation of tobramycin in adult and pediatric populations. Tobramycin pulmonary absorption and pharmacokinetics were simulated using GastroPlus™.
Physiologically-based pharmacokinetic {PBPK) models for prediction of time-dependent enzyme inhibition (TDI): effect of diltiazem on midazolam and quinidine
Purpose of the study was to optimize a PBPK model to predict timedependent and competitive inhibition of CYP 3A4 by diltiazem...
Pharmacokinetics of dietary cancer chemopreventive compound dibenzoylmethane in rats and the impact of nanoemulsion and genetic knockout of Nrf2 on its disposition
The pharmacokinetic disposition of a dietary cancer chemopreventive compound dibenzoylmethane (DBM) was studied in male Sprague-Dawley rats after intravenous...
Impressions of Monet.
I recently had the occasion to visit the Monet exhibition at the Grand Palais in Paris. Several things about this exhibit blew me away.
New Graph Library
A new graph library that provides the right graphs at the right time and with the right information has been developed by Cognigen Corporation, a leading provider of pharmacometric analysis and support services. Comprehensive graphical exploratory data analysis is essential to building pharmacometric models of drug behavior. Previously, deciding which graphs were required to describe the data and then creating a new program for each graph consumed excessive time from both scientists and programmers.
Trends in kinase selectivity: insights for target class-focused library screening
A kinome-wide selectivity screen of >20000 compounds with a rich representation of many structural classes has been completed.
Simulations Plus Reports Preliminary Revenues for First Fiscal Quarter of FY2011
Record First Quarter and Sustained Multi-year Growth Trend
Simulations Plus Reports FY2010 and Fourth Quarter FY2010 Financial Results
Fiscal Year Earnings Jump 52.7% on 17.2% Revenue Increase
Simulations Plus Sets Date for 4 th Quarter and Fiscal Year 2010 Earnings Release and Conference Call
Conference Call to be on Tuesday, November 30, at 4:15 PM EST
Learning to be an architect of ideas.
I have long been addicted to The New York Times Book Review. It is not that I am a writer groupie as much as I find it fascinating to read about how a book came about.
Development of A Mechanistic in vitro – in vivo Correlation for Theophylline
Theophylline is used to prevent and treat wheezing, shortness of breath, and difficulty breathing caused by asthma, chronic bronchitis, emphesema, and other lung diseases. Immediate release oral…
Application of a Respiratory PBPK Model for Predicting Deposition and Disposition following Inhaled Administration of Morphine
Demonstrate the pulmonary component of the GastroPlus™ Additional Dosage Routes Module™ (ADRM) simulation to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for inhaled…
Mechanistic PBPK Simulation in Place of In Vivo Drug-Drug Interaction (DDI) Studies for Compliance with Regulatory Requirements of EMA and FDA
To highlight the application and validation of PBPK DDI simulation results obtained using GastroPlus™ in compliance with newly proposed European Medicines Agency (EMA) and US FDA guidelines for the…
You WILL Innovate!
Few among us would think highly of a leader who directed us to innovate on demand. After all, innovation is something that comes from a mysterious creative force that strikes like lightning to the fortunate inventor, bringing with it fame and fortune. Think Bill Hewlett and Dave Packard; Steve Jobs and Steve Wozniak; Bill Gates; Mark Zuckerberg; or Tim Berners-Lee (huh?) [1].
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma
The pharmacokinetic profiles of bendamustine and active metabolites were defined in patients with rituximab-refractory, relapsed indolent B-cell non-Hodgkin's lymphoma, and supported understanding of exposure-response relationships for efficacy and safety.
Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug
The objective of this study was to assess the impact of observed in vitro dissolution rate differences on in vivo pharmacokinetics for two enteric-coated bead formulations...
Model hurricanes.
Although some meteorological modelers may disagree, it seems to me that models predicting development and movement of hurricanes are getting more and more accurate.
But…my projects are special.
Scientists in the field of pharmaceutical research and development face a most daunting challenge. Our understanding of the diseases we work to treat grows more complex and perplexing with each new published study. Take, for example, the gusher of information coming out on Alzheimer’s disease. How can research findings from genetics, neurology, nutrition, protein chemistry, pharmacology, and epidemiology (just to name a few) be tracked, sorted, and used?